Cargando…

Targeting radiation‐induced upstream stimulatory factor‐1 by histone deacetylase inhibitors to reverse radioresistance in prostate cancer

BACKGROUND: Ionizing radiation (IR) is a standard modality for the management of solid tumors. Apart from its killing effects, IR can induce pro‐survival factors leading to radioresistance of cancer. Mechanistic understanding of radiation resistance is warranted to overcome the pro‐survival effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Seema, Ahmed, Mansoor M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780427/ https://www.ncbi.nlm.nih.gov/pubmed/34533293 http://dx.doi.org/10.1002/cnr2.1553

Ejemplares similares

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Expressions of heparanase and upstream stimulatory factor in hepatocellular carcinoma
por: Chen, Bin, et al.
Publicado: (2014)

Reversing resistance to antiandrogens with a histone deacetylase inhibitor
por: Ferrari, Anna C.
Publicado: (2018)

Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells
por: Xiao, Weiwei, et al.
Publicado: (2013)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy
por: Kraft, Fabian B., et al.
Publicado: (2023)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

Protein kinases as switches for the function of upstream stimulatory factors: implications for tissue injury and cancer
por: Horbach, Tina, et al.
Publicado: (2015)

Kbtbd11 contributes to adipocyte homeostasis through the activation of upstream stimulatory factor 1
por: Watanabe, Kazuhisa, et al.
Publicado: (2019)

Upstream Stimulatory Factors Regulate HIV-1 Latency and Are Required for Robust T Cell Activation
por: Horvath, Riley M., et al.
Publicado: (2023)

Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells
por: Yang, Wen-Bin, et al.
Publicado: (2021)

Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells
por: Kong, Dejuan, et al.
Publicado: (2012)

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma
por: Wedel, S A, et al.
Publicado: (2008)

Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer
por: Pramanik, Siddhartha Das, et al.
Publicado: (2022)

Reversible histone deacetylase activity catalyzes lysine acylation
por: Tsusaka, Takeshi, et al.
Publicado: (2023)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells
por: Gameiro, Sofia R., et al.
Publicado: (2016)

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
por: Dickinson, Michael, et al.
Publicado: (2010)

Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
por: Kalin, Jay H., et al.
Publicado: (2018)

Visible-Light-Controlled Histone Deacetylase Inhibitors for Targeted Cancer Therapy
por: Josa-Culleré, Laia, et al.
Publicado: (2023)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

Upstream Stimulatory Factors 1 and 2 Mediate the Transcription of Angiotensin II Binding and Inhibitory Protein
por: Matsuda, Miyuki, et al.
Publicado: (2013)

Corrigendum: Protein kinases as switches for the function of upstream stimulatory factors: implications for tissue injury and cancer
por: Horbach, Tina, et al.
Publicado: (2016)

Targeting histone deacetylases for the treatment of disease
por: Lawless, M W, et al.
Publicado: (2009)

Histone deacetylases as targets for antitrypanosomal drugs
por: Zuma, Aline A, et al.
Publicado: (2018)

Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor
por: Chutake, Yogesh K., et al.
Publicado: (2016)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Regulation of Immune Responses by Histone Deacetylase Inhibitors
por: Licciardi, Paul V., et al.
Publicado: (2012)

Interpreting clinical assays for histone deacetylase inhibitors
por: Martinet, Nadine, et al.
Publicado: (2011)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
por: Bishton, Mark J., et al.
Publicado: (2010)

Dual Inhibitors Against Topoisomerases and Histone Deacetylases
por: Seo, Young Ho
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_e7ffk9eaac9qdjmbb05qpb8v7q